Blood Money: The Financial Implications of Plasma Sales for Individuals and Non-Bank Lenders

Dooley, John M.; Gallagher, Emily

doi:10.2139/ssrn.3940369

Cited by 3 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The USA alone collects about 70% of the world’s plasma supply 10. A combination of a favourable regulatory environment, an extensive collection network and advanced technological infrastructure contributed to establishing the US position 11…”

Section: The Goal Of Self-sufficiency and The Burden On Countriesmentioning

confidence: 99%

“…10 A combination of a favourable regulatory environment, an extensive collection network and advanced technological infrastructure contributed to establishing the US position. 11 More broadly, countries that allow some form of payment for plasma donations-including EU member states Germany, Austria, Hungary and the Czech Republic-account for nearly 90% of the global supply. 12 The new EU regulation states that 'Compensation may consist of the reimbursement of expenses incurred in connection with SoHO donation or on making good of any losses, preferably based on quantifiable criteria, associated with the donation of SoHO'.…”

Section: The Goal Of Self-sufficiency and The Burden On Countriesmentioning

confidence: 99%

See 1 more Smart Citation

Quality and safety for substances of human origins: scientific evidence and the new EU regulations

Elias,

Lacetera,

Macis

et al. 2024

BMJ Glob Health

View full text Add to dashboard Cite

Section: The Goal Of Self-sufficiency and The Burden On Countriesmentioning

confidence: 99%

Section: The Goal Of Self-sufficiency and The Burden On Countriesmentioning

confidence: 99%

Quality and safety for substances of human origins: scientific evidence and the new EU regulations

Elias,

Lacetera,

Macis

et al. 2024

BMJ Glob Health

View full text Add to dashboard Cite

An economy of immunity: The racial‐spatial lives of antibodies in the American blood plasma economy from 1960s prisons to COVID‐19

Johnson

2024

Trans Inst British Geog

View full text Add to dashboard Cite

In 2020, a market in convalescent blood plasma developed as a potential treatment for COVID‐19. During this time, commercial plasma centres—which collect the blood plasma from paid donors for pharmaceutical production—paid recovered patients as much as US$100 for a donation of blood plasma containing COVID‐19 antibodies, from which they manufactured an experimental treatment. This paper uses the commercial collection of COVID‐19 antibodies found in plasma as an entry point into exploring how racially uneven exposures to disease may produce biovalue. The first section considers the spatial history of antibody‐derived plasma products, using historical research to examine how inmates at predominantly black plantation‐prisons in the US South were valued for antibody production in the 1960s. Against this historical relief, the second section examines the spatiality of antibodies in current practices of the plasma industry, as well as in the plasma industry's response to the COVID‐19 pandemic (even as those efforts eventually failed in clinical trials). If geographical literatures on environmental exposure, as well as on COVID‐19 transmission, discuss exposure as an outcome of racial capitalism, this paper emphasises the productive opportunities that capital can solicit from exposures, especially those that are useful to different forms of biomedicine. By critically scrutinising the practice of ‘sharing immunity’ and attending to its decidedly geographic constitution, we can see how what Ruth Wilson Gilmore calls the ‘death‐dealing logics’ of racial capitalism may also work through the seemingly affirmative practices and communal imaginaries behind the redistribution of antibodies as medicine.

show abstract

Paid plasma versus voluntary nonremunerated plasma collection for plasma-derived medicine: Iran experience with a short glance at a few countries

Pourfathollah,

Shamsasenjan,

Dehshal

2023

Glob J Transfus Med

View full text Add to dashboard Cite

Blood Money: The Financial Implications of Plasma Sales for Individuals and Non-Bank Lenders

Cited by 3 publications

References 55 publications

Quality and safety for substances of human origins: scientific evidence and the new EU regulations

Quality and safety for substances of human origins: scientific evidence and the new EU regulations

An economy of immunity: The racial‐spatial lives of antibodies in the American blood plasma economy from 1960s prisons to COVID‐19

Paid plasma versus voluntary nonremunerated plasma collection for plasma-derived medicine: Iran experience with a short glance at a few countries

Contact Info

Product

Resources

About